Literature DB >> 28731042

Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.

Naoki Oishi1, Tetsuo Kondo1, Aya Ebina2, Yukiko Sato3, Junko Akaishi4, Rumi Hino3, Noriko Yamamoto3, Kunio Mochizuki1, Tadao Nakazawa1, Hiroshi Yokomichi5, Koichi Ito4, Yuichi Ishikawa3, Ryohei Katoh1.   

Abstract

Thyroid papillary carcinoma is the most common endocrine neoplasm and generally carries a favorable prognosis. However, a small subset of papillary carcinomas transforms into anaplastic carcinoma, an undifferentiated cancer with a dismal prognosis. Recent studies using next-generation sequencing revealed the genomic landscape of papillary carcinoma and anaplastic carcinoma. However, risk factors for anaplastic transformation in papillary carcinoma remain obscure. In the present study, we investigated molecular alterations of papillary carcinoma and anaplastic carcinoma components in 27 tumors in which anaplastic carcinoma coexisted with antecedent papillary carcinoma. We conducted direct sequencing for BRAF, TERT promoter and PIK3CA, and immunohistochemistry for p53, TTF-1 and subunits of the SWI/SNF complex (ARID1A, ARID1B, ATRX, SMARCA2, SMARCA4, SMARCB1, and PBRM1). BRAFV600E and TERT promoter mutated at the rate of 90% and 95%, respectively, and these mutational statuses were almost identical between the papillary carcinoma and anaplastic carcinoma components. PIK3CA mutation was positive in 33% of our samples with a heterogeneous mutation pattern of the papillary carcinoma and anaplastic carcinoma components. Aberrant expression of p53 and loss of TTF-1 were present in 63 and 59%, respectively, and these two alterations were confined to the anaplastic carcinoma components. There was a loss of the SWI/SNF complex in a subset of the tumors with a heterogeneous pattern of the papillary carcinoma and anaplastic carcinoma components: SMARCA4 in 4% and PBRM1 in 4%. In a multivariate comparison between the antecedent papillary carcinoma components and control papillary carcinomas without anaplastic transformation, TERT promoter mutation was independently associated with anaplastic transformation. Collectively, papillary carcinoma-derived anaplastic carcinomas are characterized by BRAF and TERT promoter mutations, and these mutations occur prior to anaplastic transformation. Alterations of PIK3CA and the SWI/SNF complex are relatively rare and temporally heterogeneous. Of note, a papillary carcinoma harboring TERT promoter mutation is at higher risk for anaplastic transformation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28731042     DOI: 10.1038/modpathol.2017.75

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  42 in total

Review 1.  Poorly differentiated and anaplastic thyroid cancer.

Authors:  Kepal N Patel; Ashok R Shaha
Journal:  Cancer Control       Date:  2006-04       Impact factor: 3.302

2.  Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer.

Authors:  Takahiro Oike; Hideaki Ogiwara; Takashi Nakano; Jun Yokota; Takashi Kohno
Journal:  Jpn J Clin Oncol       Date:  2013-07-30       Impact factor: 3.019

3.  Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.

Authors:  Vlasta Sykorova; Sarka Dvorakova; Josef Vcelak; Eliska Vaclavikova; Tereza Halkova; Daniela Kodetova; Petr Lastuvka; Jan Betka; Petr Vlcek; Martin Reboun; Rami Katra; Bela Bendlova
Journal:  Anticancer Res       Date:  2015-04       Impact factor: 2.480

4.  Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Authors:  Kimberly C Wiegand; Anna F Lee; Osama M Al-Agha; Christine Chow; Steve E Kalloger; David W Scott; Christian Steidl; Sam M Wiseman; Randy D Gascoyne; Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-05-18       Impact factor: 7.996

5.  Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.

Authors:  Naoki Oishi; Tetsuo Kondo; Tadao Nakazawa; Kunio Mochizuki; Tomohiro Inoue; Kazunari Kasai; Ippei Tahara; Tomonori Yabuta; Mitsuyoshi Hirokawa; Akira Miyauchi; Ryohei Katoh
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

6.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

7.  Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.

Authors:  Roch-Philippe Charles; Jillian Silva; Gioia Iezza; Wayne A Phillips; Martin McMahon
Journal:  Mol Cancer Res       Date:  2014-04-25       Impact factor: 5.852

Review 8.  TERT promoter mutations in thyroid cancer.

Authors:  Rengyun Liu; Mingzhao Xing
Journal:  Endocr Relat Cancer       Date:  2016-01-05       Impact factor: 5.678

9.  Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas.

Authors:  Jaime Miguel Pita; Inês Filipa Figueiredo; Margarida Maria Moura; Valeriano Leite; Branca Maria Cavaco
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

10.  The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.

Authors:  T Liu; N Wang; J Cao; A Sofiadis; A Dinets; J Zedenius; C Larsson; D Xu
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867

View more
  26 in total

1.  Coexisting well-differentiated and anaplastic thyroid carcinoma in the same primary resection specimen: immunophenotypic and genetic comparison of the two components in a consecutive series of 13 cases and a review of the literature.

Authors:  Moira Ragazzi; Federica Torricelli; Benedetta Donati; Alessia Ciarrocchi; Dario de Biase; Giovanni Tallini; Eleonora Zanetti; Alessandra Bisagni; Elisabetta Kuhn; Davide Giordano; Andrea Frasoldati; Simonetta Piana
Journal:  Virchows Arch       Date:  2020-07-18       Impact factor: 4.064

2.  Molecular therapeutics for anaplastic thyroid cancer.

Authors:  Nikita Pozdeyev; Madison M Rose; Daniel W Bowles; Rebecca E Schweppe
Journal:  Semin Cancer Biol       Date:  2020-01-25       Impact factor: 15.707

3.  Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience.

Authors:  Nobuyuki Bandoh; Toshiaki Akahane; Takashi Goto; Michihisa Kono; Haruyuki Ichikawa; Takahiro Sawada; Tomomi Yamaguchi; Hiroshi Nakano; Yumiko Kawase; Yasutaka Kato; Hajime Kamada; Yasuaki Harabuchi; Kazuo Shimizu; Hiroshi Nishihara
Journal:  Oncol Lett       Date:  2018-10-02       Impact factor: 2.967

4.  Prognostic Impact of the Turin Criteria in Poorly Differentiated Thyroid Carcinoma.

Authors:  Junko Akaishi; Tetsuo Kondo; Kiminori Sugino; Yuna Ogimi; Chie Masaki; Kiyomi Y Hames; Tomonori Yabuta; Chisato Tomoda; Akifumi Suzuki; Kenichi Matsuzu; Takashi Uruno; Keiko Ohkuwa; Wataru Kitagawa; Mitsuji Nagahama; Ryohei Katoh; Koichi Ito
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

5.  Primary Versus Secondary Anaplastic Thyroid Carcinoma: Perspectives from Multi-institutional and Population-Level Data.

Authors:  Tam N M Ngo; Trang T B Le; Thoa Le; Andrey Bychkov; Naoki Oishi; Chan Kwon Jung; Lewis Hassell; Kennichi Kakudo; Huy Gia Vuong
Journal:  Endocr Pathol       Date:  2021-09-24       Impact factor: 3.943

6.  Comparison of sonographic characteristics of primary thyroid lymphoma and anaplastic thyroid carcinoma.

Authors:  Li-Shuang Gu; Ning-Yi Cui; Yong Wang; Shu-Nan Che; Shuang-Mei Zou; Wen He; Jun-Ying Liu; Xuan-Tong Gong
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

7.  Cytomorphologic Spectrum of SMARCB1-Deficient Soft Tissue Neoplasms.

Authors:  Inga-Marie Schaefer; Alyaa Al-Ibraheemi; Xiaohua Qian
Journal:  Am J Clin Pathol       Date:  2021-07-06       Impact factor: 2.493

Review 8.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

9.  2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer.

Authors:  Keith C Bible; Electron Kebebew; James Brierley; Juan P Brito; Maria E Cabanillas; Thomas J Clark; Antonio Di Cristofano; Robert Foote; Thomas Giordano; Jan Kasperbauer; Kate Newbold; Yuri E Nikiforov; Gregory Randolph; M Sara Rosenthal; Anna M Sawka; Manisha Shah; Ashok Shaha; Robert Smallridge; Carol K Wong-Clark
Journal:  Thyroid       Date:  2021-03       Impact factor: 6.568

10.  Progression of Papillary Thyroid Carcinoma to Anaplastic Carcinoma in Metastatic Lymph Nodes: Solid/Insular Growth and Hobnail Cell Change in Lymph Nodes Are Predictors of Subsequent Anaplastic Transformation.

Authors:  Toru Odate; Naoki Oishi; Masataka Kawai; Ippei Tahara; Kunio Mochizuki; Junko Akaishi; Koichi Ito; Ryohei Katoh; Tetsuo Kondo
Journal:  Endocr Pathol       Date:  2021-03-24       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.